IL6 and neoplasm: The dose–response analysis of low-affinity FolR1-TCB targeting high- and low-expression cells (Fig. 5c) showed that there was only minimal tumor lysis and no IL6 release in the low-expression cell line, suggesting that low-expression tissues would be minimally targeted by the low-affinity variant.